Clinical trial NCT01695707: Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Official title: Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Atopic Dermatitis
Keywords: atopic dermatitis
eczema
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First posted: 2012-09-28
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Many patients with eczema (atopic dermatitis) have an inherent defect in their skin barrier as demonstrated by high water loss. In laboratory conditions, studies have shown that pioglitazone restores the skin barrier function in skin from eczema patients. The purpose of this study is to determine if taking pioglitazone improves the skin barrier function in people with eczema.

Detailed description: Enrolled patients will be randomized to either placebo or pioglitazone. Each randomized subject will have a skin biopsy and skin irritancy assay performed prior to treatment and at the end of 12 weeks of treatment. Noninvasive barrier measurements including transepidermal water loss will be recorded at all study visits.

Eligibility criteria: Inclusion Criteria:

* i. Moderate to Severe AD: EASI ≥ 10 ii. Active Atopic Dermatitis: Subjects must have within the last 3 months according to medical records or by medical exam of the investigator:

  * Pruritus
  * Eczema (acute, subacute, chronic)

I. Typical morphology and age-specific patterns - Patterns include (1) facial, neck, and extensor involvement in infants and children, (2) current or prior flexural lesions in any age group, (3) sparing groin and axillary regions.

II. Chronic or relapsing history

iii. Extrinsic they must also meet both of the following: serum total IgE ≥ 1.5 S.D. greater than the age-matched norms and positive multi-allergen RAST (Phadiatop).

Additionally, subjects must have TEWL of nonlesional skin of upper arm that is ≥ 8 gm/m2/h at screening visit. This is to ensure that we are in fact studying the subset of AD subjects who have a skin barrier defect.

Exclusion Criteria:

* Unwillingness or inability to complete the Informed Consent process
* Subjects with a history of keloid formation
* History of lidocaine or Novocain allergy
* Subjects with a systemic infection requiring a course of systemic antibiotics or antivirals within the last 2 weeks
* Subjects with MD diagnosed Type 1 or 2 diabetes mellitus
* Subjects with NYHA class III or IV cardiac status
* Subjects with a history of liver disease (EtOH, viral hepatitis, drug-induced hepatitis or other)
* Subjects with evidence of an underlying systemic disease based on history and physical (other than the above diagnostic categories (and associated allergic disorders), or well-controlled hypertension, or hyperlipidemia).
* History of cancer other than nonmelanomatous skin cancer or cervical dysplasia
* Participants enrolled while on a systemic treatment for their atopic dermatitis (e.g. cyclosporine, mycophenolate mofetil) must remain on a stable dose for the duration of the study

Primary outcomes:
measure: Noninvasive barrier measurements (TEWL)
measure: Transepithelial electrical resistance (TEER) and permeability
measure: mRNA
Secondary outcomes:
measure: Skin Irritancy
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester Medical Center
state: New York
Study officials:
affiliation: University of Rochester
name: Lisa A Beck, MD
role: PRINCIPAL_INVESTIGATOR
References: